P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Clinical Investigation

• Publication date

  1996-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI118699PMID 8647944PMCID PMC507337
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• On the pharmacokinetics of domperidone in animals and man I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats

  2010cited by this paper
• Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.

  1995cited by this paper
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

  1995influential reference
• MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy

  1995cited by this paper
• A method to determine the ability of drugs to diffuse through the blood-brain barrier.

  1994cited by this paper
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

  1994influential reference
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells.

  1993cited by this paper
• Modulation of multidrug resistance: at the threshold.

  1993cited by this paper
• Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone.

  1992cited by this paper
• In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

  1991cited by this paper
• Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities

  1990cited by this paper
• The biochemistry of P-glycoprotein-mediated multidrug resistance.

  1989cited by this paper
• Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia.

  1989cited by this paper
• Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

  1989influential reference
• The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues

  1989cited by this paper
• Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

  1989cited by this paper
• Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes.

  1989cited by this paper
• Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

  1988cited by this paper
• The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus.

  1988cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

  1986cited by this paper
• Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins.

  1986cited by this paper
• Restrictive Transport of a Lipid‐Soluble Peptide (Cyclosporin) Through the Blood–Brain Barrier

  1985cited by this paper
• The blood-brain barrier. Transport across the cerebral endothelium.

  1985cited by this paper
• Domperidone

  1982cited by this paper
• Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.

  1980cited by this paper
• Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity.

  1979cited by this paper
• A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

  1976cited by this paper
• Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 1: in vivo oral pharmacology and acute toxicity. Comparison with morphine, codeine, diphenoxylate and difenoxine.

  1974cited by this paper
• Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 2: in vivo parenteral pharmacology and acute toxicity in mice. Comparison with morphine, codeine and diphenoxylate.

  1974influential reference
• The Pharmacological Basis of Therapeutics

  1966influential reference
• The Pharmacological Basis of Therapeutics

  1941cited by this paper

• Managing Drug–Drug Interactions Involving the Non‐Prescription Opioid Loperamide Through Physiologically Based Pharmacokinetic Modeling

  2026cites this paper
• Glucosamine activates intestinal P-glycoprotein inhibiting drug absorption

  2025cites this paper
• Precision medication based on the evaluation of drug metabolizing enzyme and transporter functions

  2025cites this paper
• In vitro and in silico evaluation of the interaction of yohimbine with drug transporters and cytochrome P450 isoenzymes.

  2025cites this paper
• In vitro assessment of P-glycoprotein-mediated antiseizure medications efflux in a blood-brain barrier cell model.

  2025cites this paper
• Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance

  2025cites this paper
• Neuroprotective Effects of Metformin Through the Modulation of Neuroinflammation and Oxidative Stress

  2025cites this paper
• Effect of Rifampicin on Serum Clozapine Concentration/Daily Dose (C/D) Ratio: Case Series and Literature Review.

  2025cites this paper
• Structural insights into binding-site access and ligand recognition by human ABCB1

  2025cites this paper
• Nose to brain strategy coupled to nano vesicular system for natural products delivery: Focus on synaptic plasticity in Alzheimer's disease

  2024cites this paper
• Brain drug delivery from the nasal olfactory region is enhanced using lauroylcholine chloride: An estimation using in vivo PET imaging.

  2024cites this paper
• The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications

  2024cites this paper
• The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.

  2024cites this paper
• The Active Glucuronide Metabolite of the Brain Protectant IMM-H004 with Poor Blood–Brain Barrier Permeability Demonstrates a High Partition in the Rat Brain via Multiple Mechanisms

  2024cites this paper
• A Review on Simultaneous Estimation of combination of Omeprazole and Domperidone in Bulk and Tablet by RP-HPLC Method

  2024cites this paper
• Loperamide positive deaths in Sweden 2012-2022 and Finland 2017-2022: Fatal loperamide intoxication exclusively for Sweden.

  2024cites this paper
• Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?

  2024cites this paper
• Structural insight into binding site access and ligand recognition by human ABCB1

  2024cites this paper
• The Blood-Brain Barrier: Composition, Properties, and Roles in Brain Health.

  2024cites this paper
• Pharmacokinetic Modeling of the Effect of Tariquidar on Ondansetron Disposition into the Central Nervous System

  2024cites this paper
• Albendazole - Ivermectin combination decreases inflammation in experimental neurocysticercosis.

  2023cites this paper
• The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics.

  2023cites this paper
• Transcranial Focal Electric Stimulation Avoids P-Glycoprotein Over-Expression during Electrical Amygdala Kindling and Delays Epileptogenesis in Rats

  2023cites this paper
• Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys.

  2023cites this paper
• Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice

  2023cites this paper
• P‐Glycoprotein‐Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P‐Glycoprotein‐Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database

  2023cites this paper
• Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?

  2023cites this paper
• Proteasome inhibition protects blood–brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer’s disease model

  2023cites this paper
• Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

  2023cites this paper
• Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

  2023cites this paper
• Review article: An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis

  2023cites this paper
• The Potential Mechanisms behind Loperamide-Induced Cardiac Arrhythmias Associated with Human Abuse and Extreme Overdose

  2023cites this paper
• Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice

  2022influential citation
• Protein expression of P-glycoprotein in neocortex from patients with frontal lobe epilepsy.

  2022cites this paper
• Some New Aspects of Genetic Variability in Patients with Cutaneous T-Cell Lymphoma

  2022cites this paper
• Canine and feline P‐glycoprotein deficiency: What we know and where we need to go

  2022cites this paper
• The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery

  2022cites this paper
• P-glycoprotein and cancer: what do we currently know?

  2022cites this paper
• Multifunctional Polymeric Micelles for Cancer Therapy

  2022cites this paper
• ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

  2022cites this paper
• P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease

  2022cites this paper
• The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial

  2022cites this paper
• Brain-Targeted Drug Delivery System: A Novel Approach

  2022cites this paper
• Structure‐based alteration of tryptophan residues of the multidrug transporter CmABCB1 to assess substrate binding using fluorescence spectroscopy

  2022cites this paper
• Drug therapy in pregnant and nursing women

  2022cites this paper
• Generation of a homozygous mutant drug transporter (ABCB1) knockout line in the sea urchin Lytechinus pictus

  2022cites this paper
• Targetability of the neurovascular unit in inflammatory diseases of the central nervous system

  2022cites this paper
• ATP-binding cassette (ABC) drug transporters in the developing blood–brain barrier: role in fetal brain protection

  2022cites this paper
• Copper bis(thiosemicarbazone) complexes modulate P‐glycoprotein expression and function in human brain microvascular endothelial cells

  2022cites this paper
• Ether lipid transfer across the blood-brain and placental barriers does not improve by inactivation of the most abundant ABC transporters.

  2022cites this paper
• and does

  2022cites this paper
• Immune Response Is Key to Genetic Mechanisms of SARS-CoV-2 Infection With Psychiatric Disorders Based on Differential Gene Expression Pattern Analysis

  2022cites this paper
• Is Oral Lipid-Based Delivery for Drug Targeting to the Brain Feasible?

  2022cites this paper
• Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics

  2022cites this paper
• Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain

  2022cites this paper
• Cardiac glycoside-mediated turnover of Na, K-ATPases as a rational approach to reducing cell surface levels of the cellular prion protein

  2022cites this paper
• Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity S

  2022influential citation
• Comparison of the Blood–Brain Barrier Transport and Vulnerability to P-Glycoprotein-Mediated Drug–Drug Interaction of Domperidone versus Metoclopramide Assessed Using In Vitro Assay and PET Imaging

  2022influential citation
• Acute Extrapyramidal Side Effects Following Domperidone Intake in a 48-Year-Old Female Patient: The First Genetic Alteration and Drug Interaction Characterized

  2022cites this paper
• A Rare Case of Domperidone-Induced Acute Dystonia in a Young Adult Due to Consumption of Combination Drug (Proton Pump Inhibitors With Domperidone) and Its Possible Pathomechanism

  2022cites this paper
• Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity

  2021influential citation
• P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.

  2021cites this paper
• First Sequencing of Caprine Mdr1 (Abcb1) mRNA Due to Suspected Neurological Adverse Drug Reaction in a Thuringian Goat Following Extra-Label Use of Doramectin

  2021cites this paper
• The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors

  2021cites this paper
• Mechanistic Modeling of Placental Drug Transfer in Humans: How Do Differences in Maternal/Fetal Fraction of Unbound Drug and Placental Influx/Efflux Transfer Rates Affect Fetal Pharmacokinetics?

  2021cites this paper
• Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption

  2021cites this paper
• The association between MDR1 C3435T genetic polymorphism and the risk of multidrug-resistant epilepsy in Egyptian children

  2021cites this paper
• Heartworm disease – Overview, intervention, and industry perspective

  2021cites this paper
• Sensitive LC-MS/MS Methods for Amphotericin B Analysis in Cerebrospinal Fluid, Plasma, Plasma Ultrafiltrate, and Urine: Application to Clinical Pharmacokinetics

  2021cites this paper
• An 80-Year-Old Woman with Alzheimer Disease and Accidental Poisoning with Pyrethroid Pesticide Successfully Treated with Intravenous Lipid Emulsion

  2021cites this paper
• Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions

  2021cites this paper
• Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.

  2021cites this paper
• Participation of Monocarboxylate Transporter 8, But Not P-Glycoprotein, in Carrier-Mediated Cerebral Elimination of Phenytoin across the Blood-Brain Barrier

  2021cites this paper
• The Pharmacology of Xenobiotics after Intracerebro Spinal Fluid Administration: Implications for the Treatment of Brain Tumors

  2021cites this paper
• Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?

  2021influential citation
• PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats.

  2021cites this paper
• The ABCB Multidrug Resistance Proteins Do Not Contribute to Ivermectin Detoxification in the Colorado Potato Beetle, Leptinotarsa decemlineata (Say)

  2020cites this paper
• Donepezil, a cholinesterase inhibitor used in Alzheimer's disease therapy, is actively exported out of the brain by abcb1ab p-glycoproteins in mice.

  2020cites this paper
• Therapeutic drugs modulate ATP-Binding cassette transporter-mediated transport of amyloid beta(1-42) in brain microvascular endothelial cells.

  2020cites this paper
• Hydroethanolic extract from Endopleura uchi (Huber) Cuatrecasas and its marker bergenin: Toxicological and pharmacokinetic studies in silico and in vivo on zebrafish

  2020cites this paper
• Relevance of Transporters in Clinical Studies

  2020cites this paper
• The Blood-Brain Barrier Interface in Diabetes Mellitus: Dysfunctions, Mechanisms, and Approaches to Treatment.

  2020cites this paper
• Transfer of rhodamine-123 into the brain and cerebrospinal fluid of fetal, neonatal and adult rats

  2020cites this paper
• Strategies to Modulate the Blood-Brain Barrier for Directed Brain Tumor Targeting

  2020cites this paper
• A review: Brain specific delivery

  2020cites this paper
• The Role of P-Glycoprotein at the Blood–Brain Barrier in Neurological and Psychiatric Disease

  2020cites this paper
• Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.

  2020cites this paper
• Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.

  2020cites this paper
• A Causal Role for Gastric Rhythm in Human Disgust Avoidance.

  2020cites this paper
• Brain Distribution of Drugs: Pharmacokinetic Considerations.

  2020cites this paper
• Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters

  2020influential citation
• Structure and Function of Hepatobiliary ATP Binding Cassette Transporters.

  2020cites this paper
• Effect of P-glycoprotein on the availability of oxime reactivators in the brain.

  2020cites this paper
• 伊布替尼在原发性中枢神经系统淋巴瘤中的应用

  2020cites this paper
• The influence of genetic and epigenetic factors as covariates of the tolerability and therapeutic response to olanzapine in the treatment of psychotic diseases

  2020cites this paper
• Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells

  2020cites this paper
• Long-term Buprenorphine Treatment for Loperamide Use Disorder: A Case Series

  2020cites this paper
• The effect of breed, sex, and drug concentration on the pharmacokinetic profile of ivermectin in cattle.

  2020cites this paper
• OATP1A2 and OATP2B1 are interacting with dopamine receptor agonists and antagonists.

  2020cites this paper
• Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans

  2020cites this paper